Live Marvell Technology Vote →

Never Miss Important Company Updates Again

Get AI-powered summaries of SEC filings delivered to your inbox

Follow your favorite stocks and get email alerts when they release important updates. Completely free.

Covers 5,000+ public companies
Get started →
Sign up to stay up to date with the stocks you care about
Follow Fulcrum Therapeutics, Inc.

Get SEC filing alerts via email and in your feed for Fulcrum Therapeutics, Inc.

FULC

Fulcrum Therapeutics, Inc.

About Fulcrum Therapeutics, Inc.

Fulcrum Therapeutics is a biopharmaceutical company focused on developing small molecules to treat genetically defined rare diseases, particularly hematologic conditions like sickle cell disease. Its pipeline includes product candidates aimed at increasing fetal hemoglobin levels and addressing underlying genetic causes. The company leverages proprietary discovery platforms, collaborates with industry partners, and relies on contract manufacturing, targeting high unmet medical needs with a focus on innovation and targeted therapies.
This description was generated via AI from an annual report. Updated 8 months ago.

Latest SEC Filings from Fulcrum Therapeutics, Inc.

1
1
Fulcrum Therapeutics, Inc. Fulcrum Therapeutics Reports $18.9 Million Net Loss in Q1 2026, Adjusts Development Pipeline

Via official filing (AI summary) | about 1 month ago | 0 comments

2
1
Fulcrum Therapeutics, Inc. Fulcrum Therapeutics Reports $74.9 Million Net Loss for Fiscal Year 2025

Via official filing (AI summary) | 3 months ago | 0 comments

3
1
Fulcrum Therapeutics, Inc. Fulcrum Therapeutics Reports $19.6 Million Net Loss in Q3 2025, Sees Decrease in Operating Expenses

Via official filing (AI summary) | 7 months ago | 0 comments

4
1
Fulcrum Therapeutics, Inc. Fulcrum Therapeutics Reports No Collaboration Revenue and $17.3 Million Net Loss for Q2 2025

Via official filing (AI summary) | 10 months ago | 0 comments

5
1
Fulcrum Therapeutics, Inc. Fulcrum Therapeutics Reports $17.7 Million Net Loss in Q1 2025, Improved from Previous Year

Via official filing (AI summary) | about 1 year ago | 0 comments

6
1
Fulcrum Therapeutics, Inc. Fulcrum Therapeutics Reports Turnaround in Financial Performance, Net Income of $6.8M for Nine Months Ended September 30, 2024

Via official filing (AI summary) | over 1 year ago | 0 comments